View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, Aug. 30 (HealthDay News) -- Linzess (linaclotide) has been approved by the U.S. Food and Drug Administration to treat forms of chronic constipation that don't respond to traditional treatment, and irritable bowel syndrome (IBS) accompanied by constipation, the agency said Thursday in a news release.
The National Institutes of Health estimate that some 63 million people are affected by chronic constipation, and about 15.3 million have IBS, the FDA said.
Linzess is taken once daily on an empty stomach, at least 30 minutes before the first meal. The most frequently noted adverse reaction is diarrhea.
The drug's label contains a boxed warning that it shouldn't be taken by people aged 16 or younger, the FDA said.
Linzess is produced by Cambridge, Mass.-based Ironwood Pharmaceuticals.
Medline Plus has more about constipation.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top